Geneos Wealth Management Inc. Galectin Therapeutics Inc Transaction History

Geneos Wealth Management Inc.

$2.88 Billion
Q1 2025

A detailed history of Geneos Wealth Management Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Geneos Wealth Management Inc. holds 423,235 shares of GALT stock, worth $1.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

423,235

Previous 427,435 0.98%

Holding current value

$1.6 Million

Previous $521,000 0.96%

% of portfolio

0.02%

Previous 0.01%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 21, 2025	SELL	$1.1 - $1.76 $4,620 - $7,392	-4,200 Reduced 0.98%	423,235 $516,000
Q1 2025 May 07, 2025	BUY	$1.1 - $1.76 $42,350 - $67,760	38,500 Added 9.9%	427,435 $521,000
Q4 2024 Jan 21, 2025	BUY	$0.87 - $3.0 $31,320 - $108,000	36,000 Added 10.2%	388,935 $462,000
Q3 2024 Nov 14, 2024	SELL	$2.04 - $2.86 $83,211 - $116,659	-40,790 Reduced 10.36%	352,935 $970,000
Q2 2024 Jul 23, 2024	SELL	$2.13 - $4.2 $32,216 - $63,525	-15,125 Reduced 3.7%	393,725 $889,000
Q1 2024 May 03, 2024	SELL	$1.6 - $2.44 $6,080 - $9,272	-3,800 Reduced 0.92%	408,850 $977,000
Q4 2023 Jan 26, 2024	SELL	$1.6 - $2.18 $7,520 - $10,246	-4,700 Reduced 1.13%	412,650 $684,000
Q3 2023 Oct 11, 2023	SELL	$1.38 - $1.97 $5,933 - $8,471	-4,300 Reduced 1.02%	417,350 $801,000
Q2 2023 Aug 08, 2023	SELL	$1.32 - $2.08 $7,590 - $11,960	-5,750 Reduced 1.35%	421,650 $607,000
Q1 2023 Apr 25, 2023	SELL	$1.1 - $2.4 $8,140 - $17,760	-7,400 Reduced 1.7%	427,400 $897,000
Q4 2022 Jan 30, 2023	SELL	$1.03 - $1.66 $10,712 - $17,264	-10,400 Reduced 2.34%	434,800 $491,000
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.48 $43,055 - $81,510	-32,867 Reduced 6.87%	445,200 $725,000
Q2 2022 Jul 22, 2022	BUY	$1.19 - $1.74 $3,927 - $5,742	3,300 Added 0.7%	478,067 $626,000
Q1 2022 May 16, 2022	SELL	$1.61 - $2.31 $9,660 - $13,860	-6,000 Reduced 1.25%	474,767 $764,000
Q4 2021 Feb 09, 2022	SELL	$2.07 - $3.8 $21,942 - $40,280	-10,600 Reduced 2.16%	480,767 $995,000
Q3 2021 Nov 09, 2021	SELL	$2.59 - $4.15 $2,331 - $3,735	-900 Reduced 0.18%	491,367 $1.87 Million
Q2 2021 Jul 08, 2021	SELL	$2.07 - $5.1 $40,031 - $98,628	-19,339 Reduced 3.78%	492,267 $1.56 Million
Q1 2021 Jun 17, 2021	BUY	$1.96 - $2.57 $50,960 - $66,820	26,000 Added 5.35%	511,606 $2.26 Million
Q4 2020 May 19, 2021	BUY	$2.24 - $2.87 $1 Million - $1.29 Million	448,589 Added 1211.85%	485,606 $961,000
Q2 2020 Sep 07, 2021	SELL	$1.66 - $3.15 $7,856 - $14,908	-4,733 Reduced 11.34%	37,017 $108,000
Q1 2020 Sep 07, 2021	SELL	$1.51 - $3.0 $3,020 - $6,000	-2,000 Reduced 4.57%	41,750 $80,000
Q4 2019 Sep 07, 2021	SELL	$2.79 - $4.32 $1,116 - $1,728	-400 Reduced 0.91%	43,750 $126,000
Q3 2019 Sep 07, 2021	SELL	$3.0 - $4.05 $27,000 - $36,450	-9,000 Reduced 16.93%	44,150 $160,000
Q2 2019 Sep 07, 2021	SELL	$3.61 - $5.0 $9,025 - $12,500	-2,500 Reduced 4.49%	53,150 $220,000
Q1 2019 Sep 07, 2021	SELL	$3.86 - $6.02 $15,440 - $24,080	-4,000 Reduced 6.71%	55,650 $284,000
Q3 2018 Sep 07, 2021	BUY	$3.68 - $6.93 $174,064 - $327,789	47,300 Added 383.0%	59,650 $358,000
Q2 2018 Sep 07, 2021	SELL	$3.16 - $9.16 $91,766 - $266,006	-29,040 Reduced 70.16%	12,350 $78,000
Q1 2018 Sep 07, 2021	SELL	$3.78 - $5.97 $121,319 - $191,607	-32,095 Reduced 43.68%	41,390 $196,000
Q4 2017 Sep 07, 2021	BUY	$1.54 - $3.34 $7,504 - $16,275	4,873 Added 7.1%	73,485 $245,000
Q3 2017 Sep 07, 2021	BUY	$1.67 - $2.3 $13,360 - $18,400	8,000 Added 13.2%	68,612 $146,000
Q2 2017 Sep 07, 2021	BUY	N/A	4,000 Added 7.07%	60,612 $149,000
Q1 2017 Sep 07, 2021	BUY	N/A	4,000 Added 7.6%	56,612 $130,000
Q4 2016 Sep 07, 2021	BUY	N/A	1,800 Added 3.54%	52,612 $51,000
Q1 2016 Sep 07, 2021	BUY	N/A	50,812	50,812 $73,000

Others Institutions Holding GALT

# of Institutions

Shares Held

11.1M

Call Options Held

136K

Put Options Held

370K

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $224M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.

Account

Geneos Wealth Management Inc. Galectin Therapeutics Inc Transaction History